Sign in

First CRISPR therapy approved

2023Big moment

A gene-editing treatment for sickle cell disease is approved.

The story

On November 16, 2023, the United Kingdom's medicines regulator approved Casgevy, the first medicine in the world based on CRISPR gene editing, for sickle cell disease and a related blood disorder, beta thalassemia. The U.S. Food and Drug Administration followed on December 8, 2023 for sickle cell disease, and in January 2024 for beta thalassemia. Casgevy was developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It comes only 11 years after scientists first showed that the CRISPR system could be programmed to cut DNA at a chosen spot.

Sickle cell disease is caused by a single mutation in the gene for hemoglobin, the protein in red blood cells that carries oxygen. The faulty hemoglobin makes cells stiff and crescent-shaped, which block blood vessels and cause severe pain crises, organ damage and early death. Casgevy does not repair that mutation. Instead, doctors collect a patient's blood stem cells, use CRISPR-Cas9 (a molecular tool, adapted from a bacterial defense system, that cuts DNA where a guide RNA directs it) to switch off a gene called BCL11A, and put the cells back after the patient receives chemotherapy to clear space in the bone marrow. With BCL11A off, the body makes fetal hemoglobin again, the form babies use before birth, which does not sickle.

In the clinical trial, 29 of 30 sickle cell patients who could be evaluated had no severe pain crises for at least 12 months after treatment. Challenges remain. The process takes months, requires chemotherapy that carries risks, and was priced at $2.2 million per patient in the United States. Most people with sickle cell disease live in sub-Saharan Africa and India, where such treatment is far out of reach, and researchers are working on simpler methods, such as editing cells inside the body.

Why it mattered

  • Gene editing moved from the laboratory to routine medicine, opening a path for treating other inherited diseases.
  • Newer tools such as base editing, which changes a single DNA letter without cutting both strands, advanced quickly, including a custom therapy for an infant in 2025.
  • Debate grew over the price and fair access of one-time gene therapies and over how health systems can pay for them.
  • Companies and governments redirected investment toward editing treatments for conditions such as high cholesterol and other blood disorders.

Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made

Community notes

Loading notes…

Learn more ranked by votes

BookWalter Isaacson
The Code Breaker
Search Open Library
VideoSearch YouTube
Casgevy CRISPR sickle cell therapy
Search YouTube